Ignite Creation Date:
2024-05-05 @ 9:12 PM
Last Modification Date:
2024-10-26 @ 10:00 AM
Study NCT ID:
NCT00834002
Status:
COMPLETED
Last Update Posted:
2010-02-09
First Post:
2009-01-30
Brief Title:
Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission
Sponsor:
University Hospital Antwerp
Organization:
University Hospital Antwerp
Study Overview
Official Title:
Wilms Tumor Gene WT1 mRNA-transfected Autologous Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia AML a Phase I Trial
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CCRG 05-001
Brief Summary:
RATIONALE Vaccines made from a patients white blood cells dendritic cells and a specific leukemia antigen Wilms tumor antigen-1 may induce an effective immune response to kill residual leukemic cells andor prevent leukemia relapse
PURPOSE This phase III trial is studying the feasibility safety and efficacy of intradermal mRNA-transfected dendritic cell vaccination therapy in patients with acute myeloid leukemia
PURPOSE This phase III trial is studying the feasibility safety and efficacy of intradermal mRNA-transfected dendritic cell vaccination therapy in patients with acute myeloid leukemia
Detailed Description:
Autologous dendritic cell DC vaccination is a promising strategy for adjuvant cancer therapy in the setting of minimal residual disease MRD We performed a phase III trial in patients with acute myeloid leukemia AML where patients received intradermal injections of autologous DC loaded with mRNA coding for the Wilms tumor protein WT1 WT1 is highly overexpressed in leukemia and the level of WT1 RNA in peripheral blood is a useful biomarker for molecular diagnosis en follow-up in the MRD setting We want to prospectively monitor WT1 RNA expression in the peripheral blood of vaccinated and non-vaccinated AML patients in order to evaluate its predictive value as a biomarker for relapse and to assess the clinical efficacy of DC vaccination in acute myeloid leukemia patients We believe on the basis of already available evidence that the use of WT1 both as a target for immunotherapy as well as a biomarker not holds promise to assess the efficacy of new experimental therapeutic interventions such as DC vaccination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None